Director Bae Jeong-in Increases 20,000 Shares in Curacle (365270)

Director Bae Jeong-in of biopharmaceutical company Curacle (365270) acquired an additional 20,000 common shares through the exercise of stock purchase rights on June 8, 2026. According to the disclosure on October 10, Bae's shareholding increased by 20,000 shares compared to the previous reporting date of December 15, 2022, raising his ownership stake from 0.07% to 0.14%. The shares were acquired at a purchase price of 3,298 won. As of 2:00 PM KST on June 10, 2026, Curacle's stock price stood at 11,080 won, down 360 won from the previous day. The company's latest financial report shows total assets of 532 billion won, liabilities of 161 billion won, and equity of 371 billion won. Revenue amounted to 710 million won, with an operating loss of 165 billion won and a net loss of 181 billion won. Curacle, a R&D firm listed on the KOSDAQ since May 12, 2016, reports these figures on a standalone basis.